, Tracking Stock Market Picks
Enter Symbol:

down 99.84 %

NEUROGESX INC. (NGSX) rated Buy with price target $8 by Lazard Capital

Posted on: Thursday,  Feb 28, 2008  10:25 AM ET by Lazard Capital

Lazard Capital rated Buy NEUROGESX INC. (OTCBB: NGSX) on 02/28/2008, when the stock price was $4.20. Since
then, NEUROGESX INC. has lost 99.85% as of 08/27/2015's recent price of $0.01.
If you would have followed this Lazard Capital's recommendation on NGSX, you would have lost 99.84% of your investment in 2737 days.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company?s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration?s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/28/2008 10:25 AM Buy
4.20 8.00
as of 12/24/2008
1 Week up  6.55 %
1 Month down  -26.34 %
3 Months up  116.66 %
1 YTD up  122.22 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy